Retinal Vasculitis After a Syfovre Injection: How Rare Is It and What to Watch For
Signs to Get Checked the Same Day After a Syfovre Injection
Have you had a Syfovre (also called pegcetacoplan) injection? Call your retina specialist the same day if you notice any of these signs. Watch most closely in the first few weeks:
- New or worse blurry vision, or a drop in how well you see
- Eye pain that is getting worse, not better
- More redness in the eye
- A new shower of floaters (specks or cobwebs that drift across your view)
- New trouble with bright light
Retinal vasculitis is a rare problem after Syfovre in which the retina's small blood vessels get inflamed, and in reported cases people noticed blurry vision, eye pain, redness, a swollen eyelid, or floaters1. Some soreness right after a shot is normal. A small red patch on the white of the eye is normal too. A few new floaters can be normal. The signs above are different. They tend to get worse over days. Catching them early gives your doctor the best chance to treat the swelling and protect your sight.
Most of the reported vasculitis cases were occlusive, meaning the inflamed retinal blood vessels became blocked, and blocked vessels can starve the retina of oxygen and cause vision loss that may be permanent1. That is why speed matters: the sooner the inflammation is found and treated, the more retina there is to save. Being seen quickly is something you can act on, and it is the single most useful step you can take if these signs appear.
If you cannot reach your retina specialist and you have worsening pain or vision loss, go to an emergency room or an urgent eye-care service the same day rather than waiting for the next open appointment. Bring the date of your injection and the name of the medicine, Syfovre, with you. An acutely painful eye with vision loss after an eye injection can also signal endophthalmitis, an infection inside the eye, which is likewise treated urgently2, so the same fast action covers both possibilities.
Retinal Vasculitis After Syfovre at a Glance
This complication is uncommon. By October 2023, more than 100,000 vials of Syfovre had been distributed in the United States, and only a small number of confirmed retinal vasculitis cases had been reported, so the exact rate is not firmly established but the event is considered rare1. The reason it gets attention is not how often it happens but how serious it can be when it does, which is why knowing the warning signs is worthwhile even though the odds are in your favor.
Syfovre is a prescription medicine for geographic atrophy caused by age-related macular degeneration, and it is given as an injection into the eye (clinical: intravitreal injection) once every 25 to 60 days2. In dry age-related macular degeneration, the light-sensing cells of the macula slowly break down, so central vision is gradually lost while side vision is usually kept3. Syfovre is used to slow that breakdown, not to bring back vision already lost.
Here you will find what retinal vasculitis after Syfovre actually is, how it tends to show up and when, what is known about why it happens, what the reported outcomes were, and exactly when to call. The aim is to help you tell an expected post-injection ache from a sign that needs same-day attention, without frightening you away from a treatment your doctor recommended.
What Retinal Vasculitis After Syfovre Actually Means
Your retina is the light-sensing tissue at the back of the eye, and it is fed by a fine network of blood vessels. Retinal vasculitis is inflammation of those retinal blood vessels, and when it is occlusive the vessels also become blocked, cutting off blood flow to parts of the retina1. Think of it as swelling and clogging in the pipes that keep the retina alive.
When retinal vessels close off, the tissue they supply can be damaged. In the reported cases, vision at the time the problem was found was often quite reduced, with a median presenting vision of about 20/3001. That is a sobering number, and it is also the reason the response is urgent treatment rather than waiting: prompt care is aimed at stopping further loss, and outcomes depend heavily on how quickly the inflammation is controlled.
For most people on Syfovre, this never happens. The honest picture is that the complication is rare but serious, so the sensible response is neither panic nor dismissal. Keep your scheduled visits, learn the warning signs above, and act quickly if they appear. That combination is what turns a frightening possibility into a manageable one.
How Retinal Vasculitis After Syfovre Shows Up
In the national case review, the symptoms clustered in a recognizable way. Every affected eye had blurry vision, about 10 of every 14 eyes had eye pain, about 4 of every 14 had redness, about 3 of every 14 had eyelid swelling, and floaters were reported in 1 of the 14 eyes1. Blurry vision was the most consistent thread, so any unexplained drop in vision after an injection deserves a call.
In the reported series, symptoms began a median of about 10.5 days after the injection, within a range of roughly 8 to 23 days, and every case followed a person's first Syfovre injection1. Knowing this timing helps you stay alert during the window when a problem is most likely, without having to worry indefinitely.
Some sensations after an eye injection are expected and harmless: mild grittiness, a small painless red patch on the white of the eye, or a few temporary floaters. Warning signs are different in direction and intensity. Pain that grows over days, vision that drops rather than steadies, and spreading redness are the changes that should prompt a same-day call. When in doubt, describe what you feel to your retina specialist's office and let them decide whether you need to be seen.
Why This Happens and What Is Known About Risk
The reason retinal vasculitis happens after pegcetacoplan is still unknown; investigators have considered an immune reaction and other mechanisms, a manufacturing cause was not supported, and no single trigger has been identified1. It is uncomfortable not to have a tidy answer, but the practical takeaway is unchanged: because the cause cannot yet be predicted, monitoring and fast response are the tools that work.
Every reported case arose after the first pegcetacoplan injection rather than after later ones1. The Syfovre label also states that the medicine should not be given when there is active inflammation inside the eye, which is one reason your specialist examines the eye before each injection2. That pre-injection check is a built-in safeguard.
There is no reliable test that tells an individual in advance whether they will react this way, and the great majority of people never do. Your retina specialist weighs your specific situation, including how your macular degeneration is progressing, when recommending treatment. If you have questions about your own risk, that conversation is the right place to have them, because the answer depends on details this page cannot know.
Risks, Outcomes, and Weighing the Decision
The outcomes in the case series were serious in the eyes that were affected. About 8 of every 14 affected eyes lost more than three lines of vision on the eye chart, about 6 of every 14 lost more than six lines, and 2 eyes were ultimately removed because of blindness and pain1. These numbers describe a small group of people who developed the complication, not the typical experience of Syfovre treatment, and they are exactly why early recognition matters so much.
When vasculitis develops, retina specialists generally stop further Syfovre injections in that eye and treat the inflammation, often with corticosteroids, while managing any areas of blocked blood flow1. The goal of treatment is to limit damage and preserve the vision that remains. Because results vary from person to person, your specialist can explain what is realistic for your eye rather than offering a single expected outcome.
Deciding about Syfovre means holding two true things at once: it is used to slow a progressive, sight-threatening disease, and it carries a rare risk of serious inflammation. Syfovre was studied in large trials for slowing geographic atrophy, and the occlusive vasculitis cases have come to light through real-world use rather than during those trials1. Whether the trade-off is right for you is an individual judgment to make with your retina specialist, not a decision this page can make for you.
When to Call, and Who Should Manage This
Call your retina specialist the same day, or seek urgent eye care if you cannot reach them, for worsening eye pain, a drop in vision, spreading redness, a new shower of floaters, or new light sensitivity after a Syfovre injection. These are the same symptoms reported in confirmed vasculitis cases, and they can also point to other urgent post-injection problems such as infection inside the eye2, so they are worth a prompt call in every case.
Keep every scheduled follow-up visit, and do not wait for the next appointment to report a change you notice between visits. Your specialist examines the eye before each injection, which is part of how problems are caught early. If a symptom appears at an inconvenient time, call anyway; being seen a day sooner is always easier than recovering from a delay.
Retinal vasculitis after Syfovre is managed by a retina specialist, not at a routine eye exam, because it needs specialized imaging and treatment of the retinal blood vessels. If you received Syfovre, you already have such a specialist, and they are the right first call. If you are ever unsure who to contact, the clinic that gave the injection can direct you.
Common Questions About Retinal Vasculitis and Syfovre
Usually not. Mild soreness, a small painless red patch on the white of the eye, and a few brief floaters are common and expected after an eye injection, and they tend to fade within days. Vasculitis signs are different because they worsen: growing pain, dropping vision, spreading redness, or a new shower of floaters. If your symptoms are getting worse rather than better, call your retina specialist the same day so they can look.
In the reported cases, symptoms began a median of about 10.5 days after the injection, within a range of roughly 8 to 23 days1. That means the first few weeks are the window to stay especially alert. It does not mean a symptom outside that window should be ignored, but a change appearing one to three weeks after your first injection is worth a prompt call.
In the national case series, every confirmed case occurred after a person's first pegcetacoplan injection rather than after later injections1. Researchers do not fully understand why. The practical point is to be especially watchful in the weeks following your first Syfovre injection, while still reporting any new symptoms after later injections too.
It is rare. More than 100,000 vials of Syfovre had been distributed by October 2023, with only a small number of confirmed vasculitis cases reported1. Because reporting is voluntary, an exact rate is hard to pin down, but the event is uncommon. The value of knowing the warning signs comes from how serious the complication is when it does occur, not from how frequently it happens.
An uneventful first injection is reassuring, since the reported cases clustered in the first few weeks after the first dose. It is not a guarantee for the future, so it is still worth reporting any new worsening pain, vision loss, or spreading redness after later injections. Ongoing monitoring at your scheduled visits is part of how your specialist keeps the treatment as safe as possible.
More Questions, and What to Ask Your Doctor
That is a decision to make with your retina specialist, not on your own. Syfovre is used to slow a progressive, sight-threatening disease, and the serious inflammation is rare. Stopping, continuing, or switching are all options your specialist can weigh against how your macular degeneration is behaving. Bring your concerns to your next visit, and ask them to walk you through the benefits and risks for your specific eyes.
Because the complication has been linked to the injection itself, specialists are cautious about treating both eyes on the same day and often wait before treating the second eye. Retinal vasculitis with or without vessel blockage is a labeled warning for Syfovre, which is why timing and monitoring between eyes are handled carefully2. If both of your eyes are being treated, ask your specialist how they space and monitor your injections.
Treatment generally involves stopping further Syfovre in the affected eye and calming the inflammation, often with corticosteroids, along with managing any blocked areas of the retina1. The aim is to limit damage and protect remaining vision. Outcomes differ from person to person, so your specialist is the right person to tell you what to expect for your own eye rather than a single guaranteed result.
It depends on how much of the retina was affected and how quickly treatment began. In the reported cases, many eyes lost substantial vision, which is why prompt recognition and treatment are emphasized1. Some vision may be preserved with fast care, but recovery cannot be promised in advance. This uncertainty is exactly why the same-day warning signs on this page are worth memorizing.
- Given how my macular degeneration is progressing, do the benefits of Syfovre outweigh the risks for me?
- What exact symptoms should make me call you the same day after an injection?
- How do you check my eye before each injection to lower this risk?
- If both eyes need treatment, how will you space and monitor the injections?
- Who do I call, and how, if a problem appears at night or on a weekend?
- Journal of VitreoRetinal Diseases (American Society of Retina Specialists) (2024). Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee.
- DailyMed (U.S. FDA label) (2024). SYFOVRE (pegcetacoplan injection) Prescribing Information.
- MedlinePlus, U.S. National Library of Medicine (2024). Age-Related Macular Degeneration.